Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Fractyl Health, Inc. ( (GUTS) ).
On September 26, 2025, Fractyl Health, Inc. announced the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, expected to raise approximately $56 million in net proceeds. The offering, managed by BofA Securities and Evercore ISI, is anticipated to close on September 29, 2025, and aims to fund the company’s operations and capital expenditures into early 2027, potentially strengthening its position in the metabolic therapeutics industry.
The most recent analyst rating on (GUTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
Fractyl Health’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative cash flows. While recent corporate events and earnings call insights provide some optimism, the company’s financial instability and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The company aims to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies, targeting the organ-level root causes of disease. Fractyl Health is based in Burlington, MA, and holds a robust and growing intellectual property portfolio with numerous granted and pending patents both in the U.S. and internationally.
Average Trading Volume: 886,884
Technical Sentiment Signal: Sell
Current Market Cap: $71.29M
For a thorough assessment of GUTS stock, go to TipRanks’ Stock Analysis page.